The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract

Cancer

Volumn 78, Issue 4, 1996, Pages 827-833

  Chowdhury, Golam M ^a   Kojima, Keiji ^a   Kanayama, Hiro Omi ^a   Tsuji, Masahito ^a   Kurokawa, Yasushi ^a   Kagawa, Susumu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

immunohistochemical staining; MIB 1 monoclonal antibody; prognosis; proliferation index; transitional cell carcinoma; upper urinary tract

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; MONOCLONAL ANTIBODY KI 67; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY PELVIS CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NEPHROURETERECTOMY; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; URETER CANCER; URINARY TRACT CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; EVALUATION STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS;

EID: 0029758285     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960815)78:4<827::AID-CNCR20>3.0.CO;2-W     Document Type: Article

References (26)

1. Heney NM, Ahmed S, Flanagan MJ. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-6.
2. Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1990;1:199-206.
3. Hall PA, Woods AL. Immunohistochemical markers of cellular proliferation: achievements, problems and prospects. Cell Tissue Kinet 1990;23:505-22.
4. Okamura K, Miyake K, Koshikawa T, Asai J. Growth fraction of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67. J Urol 1990;144:875-8.
5. Sahin AA, Ro J, Ro JY, Blick MB, El-Naggar AK, Ordonez NG, et al. Ki-67 immunostaining in node negative stage I/ II breast carcinoma: significant correlation with prognosis. Cancer 1991;68:549-57.
6. Wintzer HO, Zipfel I, Schulte-Moning J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991;67:421-8.
7. Tungekar MF, Gatter KG, Dunnhill MS, Manson DY. Ki-67 immunostaining and survival in operable lung cancer. Histopathology 1991;19:545-50.
8. Alena S, Ilmo L, Kristina VB, Eero S. Cell proliferation correlates with prognosis in acinic cell carcinomas of salivary gland origin. Immunohistochemical study of 30 cases using the MIB-1 antibody in formalin-fixed paraffin sections. J Pathol 1994;173:13-21.
9. Gerdes J, Becker MHG, Keyt G, Cattoretti G. Immunohistochemical detection of tumor growth fraction (Ki-67 antigen) in formalin fixed and routinely processed tissues [letter to the editor] J Pathol 1992;168:85-7.
10. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin embedded tissues: an enhancement method for immunohistochemical staining based microwave oven heating of tissue section. J Histochem Cytochem 1991;39:741-8.
11. Szekeres G. Detection of the Ki-67 antigen in fixed proliferating cells [letter to the editor]. Anal Cell Pathol 1993;5:249-50.
12. Quinn CM, Wright NA. The clinical assessment of proliferation and growth in human tumors: evaluations of methods and applications as prognostic variables. J Pathol 1990; 160:93-102.
13. Meyer JS. Cell kinetic measurements of human tumors. Hum Pathol 1982;13:874-7.
14. Szyblaski W. X-ray sensitization by halopyromidines. Cancer Chemother Rep 1974;58:539-41.
15. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated cell proliferation. Int J Cancer 1983; 31:13-20.
16. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell analysis of a cell proliferation-associated human nuclear antigen defined by monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
17. Mazerolies C, Rishmann P, Chopin D, Popov Z, Malavaud B, Selves J, et al. Usefulness of MIB-1 monoclonal antibody in assessing the proliferative index in human bladder carcinoma: comparison with Ki-67 antibody. Histopathology 1994;25:563-8.
18. de Riese TW, Crabtree WN, Allhoff EP, Werner M, Liedke S, Lenis G, et al. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J Clin Oncol 1993;11:1804-8.
19. Yonemura Y, Kimura H, Ooyama S, Kamata T, Yamaguchi A, Matsumoto H. Immunocytochemical staining of proliferating cells in endoscopically biopsied tissues of gastric carcinoma with monoclonal Ki-67. Oncology 1991;48:162-5.
20. Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer 1987;60:2766-74.
21. Brawn PN. The origin of invasive carcinoma of the bladder. Cancer 1982;50:515-9.
22. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, et al. Ki-67 immunostaining in primary breast cancer: pathological clinical associations. Br J Cancer 1989; 59:943-7.
23. Gerdes J, Stein H, Pileri S, Rivano MT, Gobbi M, Ralfkiaer E, et al. Prognostic relevance of tumor-cell growth fraction in malignant non Hodgkin's lymphoma. Lancet 1987;II:448-9.
24. Youssef EM, Matsuda T, Takada N, Osugi H, Higashino M, Kinoshita H, et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 1995;76:358-66.
25. Mulder AH, Van Hootegem JCSP, Sylvester R, Ten Kate FJW, Kurth KH, Ooms ECM, et al. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J Pathol 1992;166:37-43.
26. Cher ML, Chew K, Rosenau W, Carroll PR. Cellular proliferation in prostatic adenocarcinoma as assessed by Bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 1995;26:87-93.